Public health value of universal HPV vaccination

Riccardo A. Audisio, Giancarlo Icardi, Andrea M. Isidori, Carlo Antonio Liverani, Alberto Lombardi, Luciano Mariani, Francesco Saverio Mennini, David A. Mitchell, Andrea Peracino, S. Pecorelli, G. Rezza, Carlo Signorelli, Giovanni Vitali Rosati, Gian Vincenzo Zuccotti

Research output: Contribution to journalArticle

Abstract

Background: The story of Human Papillomavirus vaccination demands reflection not only for its public health impact on the prophylactic management of HPV disease, but also for its relevant economic and social outcomes. Greater than ever data confirm the efficacy and support the urge for effective vaccination plans for both genders before sexual debut. Methods: A review of previous experience in gender-restricted vaccination programs has demonstrated a lower effectiveness. Limiting vaccination to women might increase the psychological burden on women by confirming a perceived inequality between genders; and even if all women were immunized, the HPV chain of transmission would still be maintained through men. Results: The cost-effectiveness of including boys into HPV vaccination programs should be re-assessed in view of the progressive drop of the economic burden of HPV-related diseases in men and women due to universal vaccination. The cost of the remarkable increase in anal and oropharyngeal HPV driven cancers in both sexes has been grossly underestimated or ignored. Conclusions: Steps must be taken by relevant bodies to achieve the target of universal vaccination. The analysis of HPV vaccination's clinical effectiveness vs. economic efficacy are supportive of the economic sustainability of vaccination programs both in women and men.In Europe, these achievements demand urgent attention to the social equity for both genders in healthcare. There is sufficient ethical, scientific, strategic and economic evidence to urge the European Community to develop and implement a coordinated and comprehensive strategy aimed at both genders and geographically balanced, to eradicate cervical cancer and other diseases caused by HPV in Europe.Policymakers must take into consideration effective vaccination programs in the prevention of cancers.

Original languageEnglish
Pages (from-to)157-167
Number of pages11
JournalCritical Reviews in Oncology/Hematology
Volume97
DOIs
Publication statusPublished - Jan 1 2016

Fingerprint

Vaccination
Public Health
Economics
Program Evaluation
European Union
Disease Management
Uterine Cervical Neoplasms
Cost-Benefit Analysis
Neoplasms
Psychology
Delivery of Health Care
Costs and Cost Analysis

Keywords

  • Boys
  • Cancer prevention
  • Herd immunity
  • HPV
  • Vaccination

ASJC Scopus subject areas

  • Oncology
  • Hematology
  • Geriatrics and Gerontology

Cite this

Audisio, R. A., Icardi, G., Isidori, A. M., Liverani, C. A., Lombardi, A., Mariani, L., ... Zuccotti, G. V. (2016). Public health value of universal HPV vaccination. Critical Reviews in Oncology/Hematology, 97, 157-167. https://doi.org/10.1016/j.critrevonc.2015.07.015

Public health value of universal HPV vaccination. / Audisio, Riccardo A.; Icardi, Giancarlo; Isidori, Andrea M.; Liverani, Carlo Antonio; Lombardi, Alberto; Mariani, Luciano; Mennini, Francesco Saverio; Mitchell, David A.; Peracino, Andrea; Pecorelli, S.; Rezza, G.; Signorelli, Carlo; Rosati, Giovanni Vitali; Zuccotti, Gian Vincenzo.

In: Critical Reviews in Oncology/Hematology, Vol. 97, 01.01.2016, p. 157-167.

Research output: Contribution to journalArticle

Audisio, RA, Icardi, G, Isidori, AM, Liverani, CA, Lombardi, A, Mariani, L, Mennini, FS, Mitchell, DA, Peracino, A, Pecorelli, S, Rezza, G, Signorelli, C, Rosati, GV & Zuccotti, GV 2016, 'Public health value of universal HPV vaccination', Critical Reviews in Oncology/Hematology, vol. 97, pp. 157-167. https://doi.org/10.1016/j.critrevonc.2015.07.015
Audisio, Riccardo A. ; Icardi, Giancarlo ; Isidori, Andrea M. ; Liverani, Carlo Antonio ; Lombardi, Alberto ; Mariani, Luciano ; Mennini, Francesco Saverio ; Mitchell, David A. ; Peracino, Andrea ; Pecorelli, S. ; Rezza, G. ; Signorelli, Carlo ; Rosati, Giovanni Vitali ; Zuccotti, Gian Vincenzo. / Public health value of universal HPV vaccination. In: Critical Reviews in Oncology/Hematology. 2016 ; Vol. 97. pp. 157-167.
@article{7592adf735c44ee8abd06a211f552380,
title = "Public health value of universal HPV vaccination",
abstract = "Background: The story of Human Papillomavirus vaccination demands reflection not only for its public health impact on the prophylactic management of HPV disease, but also for its relevant economic and social outcomes. Greater than ever data confirm the efficacy and support the urge for effective vaccination plans for both genders before sexual debut. Methods: A review of previous experience in gender-restricted vaccination programs has demonstrated a lower effectiveness. Limiting vaccination to women might increase the psychological burden on women by confirming a perceived inequality between genders; and even if all women were immunized, the HPV chain of transmission would still be maintained through men. Results: The cost-effectiveness of including boys into HPV vaccination programs should be re-assessed in view of the progressive drop of the economic burden of HPV-related diseases in men and women due to universal vaccination. The cost of the remarkable increase in anal and oropharyngeal HPV driven cancers in both sexes has been grossly underestimated or ignored. Conclusions: Steps must be taken by relevant bodies to achieve the target of universal vaccination. The analysis of HPV vaccination's clinical effectiveness vs. economic efficacy are supportive of the economic sustainability of vaccination programs both in women and men.In Europe, these achievements demand urgent attention to the social equity for both genders in healthcare. There is sufficient ethical, scientific, strategic and economic evidence to urge the European Community to develop and implement a coordinated and comprehensive strategy aimed at both genders and geographically balanced, to eradicate cervical cancer and other diseases caused by HPV in Europe.Policymakers must take into consideration effective vaccination programs in the prevention of cancers.",
keywords = "Boys, Cancer prevention, Herd immunity, HPV, Vaccination",
author = "Audisio, {Riccardo A.} and Giancarlo Icardi and Isidori, {Andrea M.} and Liverani, {Carlo Antonio} and Alberto Lombardi and Luciano Mariani and Mennini, {Francesco Saverio} and Mitchell, {David A.} and Andrea Peracino and S. Pecorelli and G. Rezza and Carlo Signorelli and Rosati, {Giovanni Vitali} and Zuccotti, {Gian Vincenzo}",
year = "2016",
month = "1",
day = "1",
doi = "10.1016/j.critrevonc.2015.07.015",
language = "English",
volume = "97",
pages = "157--167",
journal = "Critical Reviews in Oncology/Hematology",
issn = "1040-8428",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Public health value of universal HPV vaccination

AU - Audisio, Riccardo A.

AU - Icardi, Giancarlo

AU - Isidori, Andrea M.

AU - Liverani, Carlo Antonio

AU - Lombardi, Alberto

AU - Mariani, Luciano

AU - Mennini, Francesco Saverio

AU - Mitchell, David A.

AU - Peracino, Andrea

AU - Pecorelli, S.

AU - Rezza, G.

AU - Signorelli, Carlo

AU - Rosati, Giovanni Vitali

AU - Zuccotti, Gian Vincenzo

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Background: The story of Human Papillomavirus vaccination demands reflection not only for its public health impact on the prophylactic management of HPV disease, but also for its relevant economic and social outcomes. Greater than ever data confirm the efficacy and support the urge for effective vaccination plans for both genders before sexual debut. Methods: A review of previous experience in gender-restricted vaccination programs has demonstrated a lower effectiveness. Limiting vaccination to women might increase the psychological burden on women by confirming a perceived inequality between genders; and even if all women were immunized, the HPV chain of transmission would still be maintained through men. Results: The cost-effectiveness of including boys into HPV vaccination programs should be re-assessed in view of the progressive drop of the economic burden of HPV-related diseases in men and women due to universal vaccination. The cost of the remarkable increase in anal and oropharyngeal HPV driven cancers in both sexes has been grossly underestimated or ignored. Conclusions: Steps must be taken by relevant bodies to achieve the target of universal vaccination. The analysis of HPV vaccination's clinical effectiveness vs. economic efficacy are supportive of the economic sustainability of vaccination programs both in women and men.In Europe, these achievements demand urgent attention to the social equity for both genders in healthcare. There is sufficient ethical, scientific, strategic and economic evidence to urge the European Community to develop and implement a coordinated and comprehensive strategy aimed at both genders and geographically balanced, to eradicate cervical cancer and other diseases caused by HPV in Europe.Policymakers must take into consideration effective vaccination programs in the prevention of cancers.

AB - Background: The story of Human Papillomavirus vaccination demands reflection not only for its public health impact on the prophylactic management of HPV disease, but also for its relevant economic and social outcomes. Greater than ever data confirm the efficacy and support the urge for effective vaccination plans for both genders before sexual debut. Methods: A review of previous experience in gender-restricted vaccination programs has demonstrated a lower effectiveness. Limiting vaccination to women might increase the psychological burden on women by confirming a perceived inequality between genders; and even if all women were immunized, the HPV chain of transmission would still be maintained through men. Results: The cost-effectiveness of including boys into HPV vaccination programs should be re-assessed in view of the progressive drop of the economic burden of HPV-related diseases in men and women due to universal vaccination. The cost of the remarkable increase in anal and oropharyngeal HPV driven cancers in both sexes has been grossly underestimated or ignored. Conclusions: Steps must be taken by relevant bodies to achieve the target of universal vaccination. The analysis of HPV vaccination's clinical effectiveness vs. economic efficacy are supportive of the economic sustainability of vaccination programs both in women and men.In Europe, these achievements demand urgent attention to the social equity for both genders in healthcare. There is sufficient ethical, scientific, strategic and economic evidence to urge the European Community to develop and implement a coordinated and comprehensive strategy aimed at both genders and geographically balanced, to eradicate cervical cancer and other diseases caused by HPV in Europe.Policymakers must take into consideration effective vaccination programs in the prevention of cancers.

KW - Boys

KW - Cancer prevention

KW - Herd immunity

KW - HPV

KW - Vaccination

UR - http://www.scopus.com/inward/record.url?scp=84952639269&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84952639269&partnerID=8YFLogxK

U2 - 10.1016/j.critrevonc.2015.07.015

DO - 10.1016/j.critrevonc.2015.07.015

M3 - Article

VL - 97

SP - 157

EP - 167

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

SN - 1040-8428

ER -